Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Breast Neoplasms 1890Carcinoma, Non-Small-Cell Lung 1350Prostatic Neoplasms 983Colorectal Neoplasms 852Multiple Myeloma 741Leukemia, Myeloid, Acute 725Neoplasms 693Lung Neoplasms 680Neoplasm Metastasis 643Lymphoma 579Carcinoma, Hepatocellular 572Pancreatic Neoplasms 568Stomach Neoplasms 523Leukemia 511Recurrence 492Leukemia, Lymphocytic, Chronic, B-Cell 459Precursor Cell Lymphoblastic Leukemia-Lymphoma 452Melanoma 451Lymphoma, Non-Hodgkin 443Ovarian Neoplasms 429Lymphoma, Large B-Cell, Diffuse 423Squamous Cell Carcinoma of Head and Neck 416Myelodysplastic Syndromes 416Head and Neck Neoplasms 406Brain Neoplasms 403Rectal Neoplasms 397Glioblastoma 375Carcinoma, Renal Cell 350Hodgkin Disease 338Esophageal Neoplasms 337

Interventions

Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × OTHER × Hepatomegaly × Clear all
NCT02421354 2019-05-15

Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis

M.D. Anderson Cancer Center

Phase 2 Terminated
8 enrolled 7 charts
Myeloid

Hepatomegaly, Polycythemia Vera, Splenomegaly, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡